M Franchini

Summary

Affiliation: Azienda Ospedaliera di Verona
Country: Italy

Publications

  1. ncbi Is time to treat for HCV all the HIV/HCV co-infected hemophiliacs?
    Massimo Franchini
    Hemophilia Center, City Hospital of Verona, Verona, Italy
    Hematology 11:209-13. 2006
  2. ncbi Efficacy and safety of phlebotomy to reduce transfusional iron overload in adult, long-term survivors of acute leukemia
    Massimo Franchini
    Immunhematology and Transfusion Service, Hospital of Verona, Verona, Italy
    Transfusion 44:833-7. 2004
  3. ncbi [Clinical use of erythropoietin]
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione, Azienda Ospedaliera di Verona, Verona
    Recenti Prog Med 95:129-36; quiz 185. 2004
  4. ncbi Hereditary iron overload: update on pathophysiology, diagnosis, and treatment
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione, Azienda Ospedaliera di Verona, Italy
    Am J Hematol 81:202-9. 2006
  5. ncbi Thrombotic complications in patients with hereditary bleeding disorders
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione Centro Emofilia, Azienda Ospedale di Verona, Verona, Italy
    Thromb Haemost 92:298-304. 2004
  6. ncbi Iron overload and hematologic malignancies
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione, Centro Emofilia, Azienda Ospedaliera di Verona, 37134 Verona, Italy
    Hematol J 5:381-3. 2004
  7. ncbi High prevalence of acquired von Willebrand's syndrome in patients with thyroid diseases undergoing thyroid surgery
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione, Centro Emofilia, Azienda Ospedaliera di Verona, Verona, Italy
    Haematologica 89:1341-6. 2004
  8. ncbi [Hereditary hemocromatosis]
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione, Azienda Ospedaliera, Verona
    Recenti Prog Med 95:457-62. 2004
  9. ncbi Hepatitis C in haemophiliacs
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione Centro Emofilia, Ospedale Policlinico, via Delle Menegone 1, 37134 Verona, Italy
    Thromb Haemost 92:1259-68. 2004
  10. ncbi Dental procedures in adult patients with hereditary bleeding disorders: 10 years experience in three Italian Hemophilia Centers
    M Franchini
    Servizio di Immunoematologia e Trasfusione Centro Emofilia, Azienda Ospedaliera di Verona, Verona, Italy
    Haemophilia 11:504-9. 2005

Detail Information

Publications109 found, 100 shown here

  1. ncbi Is time to treat for HCV all the HIV/HCV co-infected hemophiliacs?
    Massimo Franchini
    Hemophilia Center, City Hospital of Verona, Verona, Italy
    Hematology 11:209-13. 2006
    ..In this concise review, the current knowledge as regards the management of HCV infection in HIV co-infected hemophiliacs is analyzed...
  2. ncbi Efficacy and safety of phlebotomy to reduce transfusional iron overload in adult, long-term survivors of acute leukemia
    Massimo Franchini
    Immunhematology and Transfusion Service, Hospital of Verona, Verona, Italy
    Transfusion 44:833-7. 2004
    ..Transfusional iron overload is a frequent finding in long-term survivors of acute leukemia (AL). Only a few studies have reported the results of iron depletion therapy in this category of patients...
  3. ncbi [Clinical use of erythropoietin]
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione, Azienda Ospedaliera di Verona, Verona
    Recenti Prog Med 95:129-36; quiz 185. 2004
    ..In this review, we briefly analyze the main clinical applications of RHuEPO, with particular attention to the potential complications deriving from its use...
  4. ncbi Hereditary iron overload: update on pathophysiology, diagnosis, and treatment
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione, Azienda Ospedaliera di Verona, Italy
    Am J Hematol 81:202-9. 2006
    ..In this review, the genetics, pathophysiology, diagnosis, clinical features, and management of these different types of hereditary hemochromatosis are briefly discussed...
  5. ncbi Thrombotic complications in patients with hereditary bleeding disorders
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione Centro Emofilia, Azienda Ospedale di Verona, Verona, Italy
    Thromb Haemost 92:298-304. 2004
    ....
  6. ncbi Iron overload and hematologic malignancies
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione, Centro Emofilia, Azienda Ospedaliera di Verona, 37134 Verona, Italy
    Hematol J 5:381-3. 2004
    ..In this review, we briefly report the present knowledge regarding the association between iron overload and hematologic malignancies...
  7. ncbi High prevalence of acquired von Willebrand's syndrome in patients with thyroid diseases undergoing thyroid surgery
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione, Centro Emofilia, Azienda Ospedaliera di Verona, Verona, Italy
    Haematologica 89:1341-6. 2004
    ..These abnormalities range from subclinical laboratory findings to hemorrhage or thromboembolism. However, the prevalence of hemostatic abnormalities in patients with thyroid diseases is still unclear...
  8. ncbi [Hereditary hemocromatosis]
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione, Azienda Ospedaliera, Verona
    Recenti Prog Med 95:457-62. 2004
    ..If phlebotomy is started before the onset of irreversible organ damages, the life expectancy of these patients is similar to that of normal population...
  9. ncbi Hepatitis C in haemophiliacs
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione Centro Emofilia, Ospedale Policlinico, via Delle Menegone 1, 37134 Verona, Italy
    Thromb Haemost 92:1259-68. 2004
    ..Finally, anti-HCV treatment should also be considered for those haemophiliacs co-infected with HIV in whom anti-retroviral treatment has stabilized the HIV infection...
  10. ncbi Dental procedures in adult patients with hereditary bleeding disorders: 10 years experience in three Italian Hemophilia Centers
    M Franchini
    Servizio di Immunoematologia e Trasfusione Centro Emofilia, Azienda Ospedaliera di Verona, Verona, Italy
    Haemophilia 11:504-9. 2005
    ..Thus, our protocol of management of patients with hereditary bleeding tendency undergoing oral treatment or surgery has been shown to be effective in preventing haemorrhagic complications...
  11. ncbi The platelet function analyzer (PFA-100): an update on its clinical use
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione, Centro Emofilia, Azienda Ospedaliera di Verona, Verona, Italy
    Clin Lab 51:367-72. 2005
    ..Given its high sensitivity, speed and simplicity of use, we conclude that the PFA-100 could replace the in vivo bleeding time as a screening test for primary hemostasis in routine clinical practice...
  12. ncbi Hemostasis and thyroid diseases revisited
    M Franchini
    Immunohematology and Transfusion Service, Hemophilia Center, Hospital of Verona, Verona, Italy
    J Endocrinol Invest 27:886-92. 2004
    ....
  13. ncbi Clinical heterogeneity of acquired hemophilia A: a description of 4 cases
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione, Azienda Ospedaliera di Verona
    Haematologica 90:ECR16. 2005
    ....
  14. ncbi Thrombosis and bleeding: when opposites are not so far apart
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione Centro Emofilia, Azienda Ospedaliera di Verona, Verona, Italy
    Clin Lab 51:173-82. 2005
    ....
  15. ncbi Recombinant factor VIIa. An update on its clinical use
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione, Centro Emofilia, Ospedale Policlinico, Piazzale Ludovico Scuro, 37134 Verona, Italy
    Thromb Haemost 93:1027-35. 2005
    ..Based on a literature search, this review examines the current knowledge on therapy with rFVIIa, from the now well-standardized uses to the newer and less well-characterised clinical applications...
  16. ncbi Hereditary hemochromatosis
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione, Azienda Ospedaliera di Verona, Verona, Italy
    Hematology 10:145-9. 2005
    ..Therapeutic phlebotomy is the mainstay of the treatment of HH. If phlebotomy is started before the onset of irreversible organ damages, the life expectancy of these patients is similar to that of normal population...
  17. ncbi Non-ABO red blood cell alloantibodies following allogeneic hematopoietic stem cell transplantation
    M Franchini
    Servizio di Immunoematologia e Trasfusione, Azienda Ospedaliera di Verona, Verona, Italy
    Bone Marrow Transplant 33:1169-72. 2004
    ....
  18. ncbi Clinical and laboratory study of an episode of cefotetan-induced severe hemolytic anemia
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione, Azienda Ospedaliera di Verona, Italy
    Hematology 9:65-9. 2004
    ..Cephalosporins are frequently associated with positive direct antiglobulin tests (DAT) and may rarely cause immune hemolytic anemia (IHA). We describe a patient who developed hemolytic anemia while she was receiving intravenous cefotetan...
  19. ncbi Treatment of hepatitis C in hemophiliacs
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione, Centro Emofilia, Azienda Ospedaliera di Verona, Verona, Italy
    Am J Hematol 81:696-702. 2006
    ..Finally, based on the encouraging results in coinfected nonhemophiliacs, anti-HCV treatment should also be considered for those HIV-positive hemophiliacs in whom anti-retroviral treatment has stabilized the HIV infection...
  20. ncbi Onset of severe refractory thrombocytopenia following surgery in a patient with type 2B von Willebrand disease--a case report
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione Centro Emofilia, Azienda Ospedaliera di Verona, Verona, Italy
    Hematology 11:127-9. 2006
    ..As platelet transfusions were ineffective due to alloimunization, effective hemostasis was achieved only with the factor VIII/von Willebrand factor concentrate Haemate P...
  21. ncbi High prevalence of inherited prothrombotic risk factors in 134 consecutive patients with von Willebrand disease
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione, Azienda Ospedaliera di Verona, Verona, Italy
    Am J Hematol 81:465-7. 2006
    ..Three carriers of multiple prothrombotic gene mutations experienced a thrombotic event. Our study suggests that the recent evidence of an association between inherited thrombotic and hemorrhagic disorders also holds true in VWD patients...
  22. ncbi The antiphospholipid syndrome
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione, Azienda Ospedaliera di Verona, Piazzale Ludovico Scuro, 37134 Verona, Italy
    Hematology 10:265-9. 2005
    ..In spite of the recent progresses, many aspects of this disease remain unclear. In this review, we briefly focus on the most important advances in the pathophysiology, diagnosis and treatment of this condition...
  23. ncbi The platelet-function analyzer (PFA-100) for evaluating primary hemostasis
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione, Centro Emofilia, Azienda Ospedaliera di Verona, Verona, Italy
    Hematology 10:177-81. 2005
    ..Given its high sensitivity, speed and simplicity of use, we conclude that the PFA-100 could replace the in vivo bleeding time as a screening test for primary hemostasis in routine clinical practice...
  24. ncbi Recombinant factor VIIa: a review on its clinical use
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione Centro Emofilia, Azienda Ospedaliera di Verona, Italy
    Int J Hematol 83:126-38. 2006
    ....
  25. ncbi Preoperative autologous blood donation in primary total knee arthroplasty: a single-centre experience on 214 consecutive patients
    M Franchini
    Servizio di Immunoematologia e Trasfusione, Azienda Ospedaliera di Verona, Verona, Italy
    Vox Sang 90:191-4. 2006
    ....
  26. ncbi The antiphospholipid syndrome: an update
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione, Azienda Ospedaliera di Verona, Verona, Italy
    Clin Lab 52:11-7. 2006
    ..The most important advances in the pathophysiology, diagnosis and treatment of this condition are discussed in this review...
  27. ncbi [Mesenchymal stem cells: from biology to clinical applications]
    Massimo Franchini
    Banca dei Tessuti della Regione Veneto, sede di Verona, Azienda Ospedaliera di Verona
    Recenti Prog Med 94:478-83. 2003
    ..Finally, we focus on the main MSC applications both in the fields of genetic and tissue engineering...
  28. ncbi The natural history of chronic hepatitis C in a cohort of HIV-negative Italian patients with hereditary bleeding disorders
    M Franchini
    Servizio di Immunoematologia e Trasfusione, Centro Emofilia, Azienda Ospedaliera di Verona, Verona, Italy
    Blood 98:1836-41. 2001
    ..The results confirm the slow progression of HCV infection in HIV-negative hemophiliacs...
  29. ncbi Recent advances in hereditary hemochromatosis
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione, Azienda Ospedaliera di Verona, Verona, Italy
    Ann Hematol 84:347-52. 2005
    ..In this review we discuss the genetics, pathophysiology, diagnosis, clinical features, and management of hereditary hemochromatosis...
  30. ncbi Interferon and ribavirin in HIV-negative haemophiliacs with chronic hepatitis C who were nonresponders to a previous interferon treatment
    M Franchini
    Servizio di Immunoematologia e Trasfusione, Centro Emofilia, Azienda Ospedaliera di Verona, Verona, Italy
    Haemophilia 8:794-7. 2002
    ..001). Our study shows that IFN and ribavirin combination therapy is effective in HIV-negative chronically HCV-infected haemophiliacs who do not respond to a previous IFN treatment...
  31. ncbi Thrombin generation assay: a useful routine check-up tool in the management of patients with haemophilia?
    G L Salvagno
    Department of Clinical Chemistry, Verona University Hospital, Verona, Italy
    Haemophilia 15:290-6. 2009
    ..We conclude that TG parameters tentatively could be a tool to tailor the global haemostatic capacity in haemophilic patients...
  32. ncbi The potential role of recombinant activated FVII in the management of critical hemato-oncological bleeding: a systematic review
    M Franchini
    1Servizio di Immunoematologia e Trasfusione Centro Emofilia, Azienda Ospedaliera di Verona, Verona, Italy
    Bone Marrow Transplant 39:729-35. 2007
    ..Thus, further trials with larger numbers of patients are needed to establish the most appropriate doses and timing of rFVIIa and to assess its efficacy and safety in this setting...
  33. ncbi Impact of different inhibitor reactivities with commercial factor VIII concentrates on thrombin generation
    G L Salvagno
    Department of Clinical Chemistry, Verona University Hospital, Verona, Italy
    Haemophilia 13:51-6. 2007
    ..The VWF-containing concentrates Fanhdi and Haemate-P, added to FVIII-deficient plasma with the presence of inhibitor, generate more thrombin than do the purified concentrates Hemofil-M and Kogenate Bayer...
  34. ncbi Efficacy and safety of factor VIII/von Willebrand's factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione, Centro Emofilia, Azienda Ospedaliera di Verona, Verona, Italy
    Haematologica 88:1279-83. 2003
    ..To evaluate the efficacy and safety of the factor VIII/von Willebrand factor concentrate Haemate-P as replacement therapy in patients with von Willebrand's disease (VWD) undergoing surgical or invasive procedures...
  35. ncbi Haemostasis and pregnancy
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione, Ospedale Policlinico, Piazzale L Scuro, 10, 37134 Verona, Italy
    Thromb Haemost 95:401-13. 2006
    ..Based on an analysis of the literature data, this review presents an overview of the main thrombotic and haemorrhagic disorders complicating pregnancy...
  36. ncbi Milestones and perspectives in coagulation and hemostasis
    Giuseppe Lippi
    Sezione di Chimica Clinica, Universita di Verona, Verona, Italy
    Semin Thromb Hemost 35:9-22. 2009
    ..The aim of this article is to provide a concise overview of the major discoveries and past and current perspectives in coagulation and hemostasis...
  37. ncbi [Menorrhagia and inherited disorders of coagulation]
    M Franchini
    Centro Emofilia, Azienda Ospedaliera, Servizio di Immunoematologia e Trasfusione, Verona, Italy
    Minerva Ginecol 54:453-60. 2002
    ..Since inherited bleeding disorders are frequently associated with menorrhagia, the conclusion is drawn that an underlying congenital bleeding disorder should be ruled out in any woman with menorrhagia...
  38. ncbi Advances in the diagnosis and management of von Willebrand disease
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione, Azienda Ospedaliera di Verona, Verona, Italy
    Hematology 11:219-25. 2006
    ..In this review, the present knowledge regarding the diagnosis and the management of VWD is briefly analyzed...
  39. ncbi Venous stasis and routine hematologic testing
    G Lippi
    Sezione di Chimica e Microscopia Clinica, Dipartimento di Scienze Morfologico Biomediche, Universita degli Studi di Verona, Verona, Italy
    Clin Lab Haematol 28:332-7. 2006
    ....
  40. ncbi Influence of temperature and time before centrifugation of specimens for routine coagulation testing
    G L Salvagno
    Sezione di Chimica e Microscopia Clinica, Dipartimento di Scienze Morfologico Biomediche, Universita degli Studi di Verona, Verona, Italy
    Int J Lab Hematol 31:462-7. 2009
    ..In conclusion, a 6-h storage of uncentrifuged specimens at either RT or 4 degrees C may still be suitable to achieve results of routine coagulation testing comprised within the analytical quality specifications for desirable bias...
  41. ncbi Efficacy of desmopressin as surgical prophylaxis in patients with acquired von Willebrand disease undergoing thyroid surgery
    M Franchini
    Servizio di Immunoematologia e Trasfusione, Istituto di Chimica e Microscopia Clinica and Dipartimento di Chirurgia, Verona, Italy
    Haemophilia 8:142-4. 2002
    ..This study highlights the need for coagulation studies in patients with thyroid diseases undergoing thyroid surgery. Subcutaneous desmopressin may be used in these patients in order to prevent a surgically related bleeding risk...
  42. ncbi Glycaemic control in athletes
    G Lippi
    Dipartimento di Scienze Morfologico Biomediche, Istituto di Chimica e Microscopia Clinica, Universita di Verona, Verona, Italy
    Int J Sports Med 29:7-10. 2008
    ....
  43. ncbi [Transfusional therapy of hemodialyzed patient with anti-Cartwright antibodies: case report and review of the literature]
    M Franchini
    Servizio di Immunoematologia e Trasfusione, Ospedale Civile Maggiore, Verona
    G Ital Nefrol 21:387-90. 2004
    ..No adverse reactions nor hemolysis were detected. CONCLUSIONS: We concluded that dialysis patients with anti-Yta antibodies could be safely transfused with blood from Cartwright positive donors...
  44. ncbi Tyr2105Cys mutation in exon 22 of FVIII gene is a risk factor for the development of inhibitors in patients with mild/moderate haemophilia A
    M Franchini
    Servizio di Immunoematologia e Trasfusione Centro Emofilia, Azienda Ospedaliera di Verona, Verona, Italy
    Haemophilia 12:448-51. 2006
    ..Based on published data, it appears that although this mutation occurs rarely in patients with mild or moderate haemophilia A, it is frequently associated with the development of high-titre inhibitors...
  45. ncbi Immunohematological aspects of bone marrow transplantation
    G Gandini
    Servizio di Immunoematologia e Transfusione, Azienda Ospedaliera di Verona, Verona, Italy
    Hematology 7:89-93. 2002
    ....
  46. ncbi [Preoperative laboratory testing]
    G Lippi
    Unità di Chimica e Microscopia Clinica, Dipartimento di Scienze Morfologico Biomediche, Universita degli Studi di Verona, Verona, Italy
    Minerva Med 96:397-407. 2005
    ..This article aims to provide a comprehensive review of the current literature on this topic, attempting to suggest a suitable approach to the puzzling issue of preoperative laboratory testing...
  47. ncbi Influence of warfarin therapy on activated factor VII clotting activity
    Giuseppe Lippi
    Istituto di Chimica e Microscopia Clinica, Dipartimento di Scienze Morfologico-Biomediche, , Verona, Italy
    Blood Coagul Fibrinolysis 17:221-4. 2006
    ..Owing to the good correlation with FVIIa:C, we also hypothesize that the PT and/or FVII:C might be employed for monitoring recombinant FVIIa therapy...
  48. ncbi Platelet count increase following phlebotomy in iron overloaded patients with liver cirrhosis
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione, Azienda Ospedaliera di Verona, Italy
    Hematology 8:259-62. 2003
    ..Our results show that phlebotomy is effective not only in lowering iron overload, but also in improving liver function and thrombocytopenia in patients with liver cirrhosis...
  49. ncbi Coagulation testing in pediatric patients: the young are not just miniature adults
    Giuseppe Lippi
    Dipartimento di Scienze Biomediche e Morfologiche, Universita di Verona, Verona, Italy
    Semin Thromb Hemost 33:816-20. 2007
    ....
  50. ncbi Thromboembolism in childhood nephrotic syndrome: a rare but serious complication
    Marco Zaffanello
    Department of Pediatrics, University of Verona, Verona, Italy
    Hematology 12:69-73. 2007
    ..Hence, predisposing factors, personal and family history of TEC, thrombosis location and evolution should be always investigated in children with NS...
  51. ncbi Pathogenesis, clinical and laboratory aspects of thrombosis in cancer
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione Centro Emofilia, Azinda ospedaliera de Verona, Ospedale Policlinico, Piazzale Ludovico Scuro, 37134, Verona, Italy
    J Thromb Thrombolysis 24:29-38. 2007
    ..In this review article, we briefly analyze the pathogenesis, laboratory, clinical and therapeutic features of cancer and thrombosis...
  52. ncbi Analysis of HFE and TFR2 gene mutations in patients with acute leukemia
    Dino Veneri
    Dipartimento di Medicina Sperimentale e Clinica, Divisione di Ematologia, Universita di Verona, 37134 Verona, Italy
    Leuk Res 29:661-4. 2005
    ..Our study does not support the evidence of an association between hemochromatosis gene mutations and iron overload in AL patients...
  53. ncbi Clinical, laboratory and therapeutic aspects of platelet-type von Willebrand disease
    M Franchini
    Servizio di Immunoematologia e Trasfusione, Centro Emofilia, Azienda Ospedaliera di Verona, Verona, Italy
    Int J Lab Hematol 30:91-4. 2008
    ..In this review, the main clinical, laboratory and therapeutic characteristics of PT-VWD are concisely reported...
  54. ncbi The use of recombinant activated factor VII in obstetric and gynaecological haemorrhage
    M Franchini
    Servizio di Immunoematologia e Trasfusione Centro Emofilia, Ospedale Policlinico Azienda Ospedaliera di Verona, Verona, Italy
    BJOG 114:8-15. 2007
    ..However, further evidence is needed to improve the assessment of its optimal dose, effectiveness and safety in such conditions...
  55. ncbi Preoperative autologous blood donation by elderly patients undergoing orthopaedic surgery
    G Gandini
    Servizio di Immunoematologia e Trasfusione Ospedale Policlinico, Via delle Menegone, 10 37134 Verona, Italy
    Vox Sang 80:95-100. 2001
    ..To assess the feasibility of a programme of predeposit in elderly patients undergoing elective orthopaedic surgery...
  56. ncbi Immune tolerance with rituximab in congenital haemophilia with inhibitors: a systematic literature review based on individual patients' analysis
    M Franchini
    Immunohematology and Transfusion Center, City Hospital of Parma, Parma, Italy
    Haemophilia 14:903-12. 2008
    ..Large prospective randomized studies with an adequate follow-up are needed to confirm these preliminary findings...
  57. ncbi Recombinant activated factor VII: mechanisms of action and current indications
    Massimo Franchini
    Servizio di Immunoematologia e Medicina Trasfusionale, Dipartimento di Patologia e Medicina di Laboratorio, Azienda Ospedaliero Universitaria di Parma, Parma, Italy
    Semin Thromb Hemost 36:485-92. 2010
    ..The agent's safety profile is also examined, along with recent advances in rFVIIa dosing and storage that may help to improve both clinical outcomes and patient quality of life...
  58. ncbi The hemostatic balance revisited through the lessons of mankind evolution
    Massimo Franchini
    Transfusion and Hemophilia Center, City Hospital of Verona, Piazzale Ludovico Scuro, 37134 Verona, Italy
    Intern Emerg Med 3:3-8. 2008
    ..The effect of inherited bleeding disorders on the development of thrombotic or atherosclerotic processes is also discussed...
  59. ncbi Acquired factor VIII inhibitors in oncohematology: a systematic review
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione Centro Emofilia, Azienda Ospedaliera di Verona, Ospedale Policlinico, and Dipartimento di Scienze Biomediche e Chirurgiche, Universita di Verona, Piazzale Ludovico Scuro, 37134 Verona, Italy
    Crit Rev Oncol Hematol 66:194-9. 2008
    ..Based on electronic and hand searches of the published literature, this systematic review examines the current knowledge on factor VIII autoantibodies associated with oncohematological disorders...
  60. ncbi Effect of Helicobacter pylori eradication on platelet count in idiopathic thrombocytopenic purpura: a systematic review and meta-analysis
    Massimo Franchini
    Immuno hematology and Transfusion Center, City Hospital, Verona, and Department of Histology, Microbiology, and Medical Biotechnology, University of Padua, Italy
    J Antimicrob Chemother 60:237-46. 2007
    ..In order to clarify this controversial issue, we performed a systematic review with meta-analysis of the available literature...
  61. ncbi Von Willebrand factor: another janus-faced hemostasis protein
    Massimo Franchini
    Immunohematology and Transfusion Centre, Department of Pathology and Laboratory Medicine, University Hospital of Parma, Italy
    Semin Thromb Hemost 34:663-9. 2008
    ..In addition, high plasma levels of VWF have been associated with an increased risk of atherothrombosis. The current article reviews the literature and provides evidence for the two-faced character that VWF therefore represents...
  62. ncbi A critical review on the use of recombinant factor VIIa in life-threatening obstetric postpartum hemorrhage
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione Centro Emofilia, Azienda Ospedaliera di Verona, Verona Italy
    Semin Thromb Hemost 34:104-12. 2008
    ..Further evidence is needed using well-designed clinical trials to better assess the optimal dose, the effectiveness, and the safety of rFVIIa in such critical bleeding conditions...
  63. ncbi Surgical prophylaxis in von Willebrand's disease: a difficult balance to manage
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione Centro Emofilia, Azienda Ospedaliera di Verona, Verona, Italia
    Blood Transfus 6:s33-8. 2008
    ....
  64. ncbi Hemophilia and cancer: a new challenge for hemophilia centers
    Massimo Franchini
    Immunohematology and Transfusion Center Department of Pathology and Laboratory Medicine, University Hospital of Parma, Parma, Italy
    Cancer Treat Rev 35:374-7. 2009
    ..These aspects, along with the epidemiology of cancer in hemophiliacs will be discussed in this review...
  65. ncbi Inhibitors in mild/moderate haemophilia A: two case reports and a literature review
    Anna Chiara Giuffrida
    Servizio di Immunoematologia e Trasfusione, Azienda Ospedaliera di Verona, Italy
    Blood Transfus 6:163-8. 2008
  66. ncbi Thyroid dysfunction and hemostasis: an issue still unresolved
    Massimo Franchini
    Dipartimento di Patologia e Medicina di Laboratorio, Azienda Ospedaliero Universitaria di Parma, Italy
    Semin Thromb Hemost 35:288-94. 2009
    ..Further trials on larger series of patients are needed to confirm these preliminary findings and to elucidate the pathogenic mechanisms regulating the complex interaction between thyroid disorders and hemostasis...
  67. ncbi Adverse reactions in blood and apheresis donors: experience from two Italian transfusion centres
    Isabella Crocco
    Servizio di Immunoematologia e Trasfusione, Azienda Ospedaliera di Verona, Verona, Italy
    Blood Transfus 7:35-8. 2009
    ....
  68. ncbi The use of recombinant factor VIIa in liver diseases
    Massimo Franchini
    Immuno hematology and Transfusion Center, City Hospital of Verona, Italy
    Blood Coagul Fibrinolysis 19:341-8. 2008
    ..In conclusion, further large randomized, controlled clinical trials are needed to better define the role of recombinant activated factor VII in the treatment of bleeding complications of liver disorders...
  69. ncbi The use of desmopressin in congenital factor XI deficiency: a systematic review
    Massimo Franchini
    Servizio di Immunoematologia e Medicina Trasfusionale, Dipartimento di Patologia e Medicina di Laboratorio, Azienda Ospedaliero Universitaria di Parma, Parma, Italy
    Ann Hematol 88:931-5. 2009
    ..However, these findings need to be supported by further trials on large population of patients...
  70. ncbi Prophylaxis in congenital hemophilia with inhibitors: the role of recombinant activated factor VII
    Massimo Franchini
    Servizio di Immunoematologia e Medicina Trasfusionale, Dipartimento di Patologia e Medicina di Laboratorio, Azienda Ospedaliero Universitaria di Parma, Parma, Italy
    Semin Thromb Hemost 35:814-9. 2009
    ..The published data on the use of rFVIIa as a prophylactic treatment in hemophilia patients with inhibitors are reviewed in this article...
  71. ncbi Laboratory, clinical and therapeutic aspects of acquired hemophilia A
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione, Centro Emofilia, Azienda Ospedaliera di Verona, Italy
    Clin Chim Acta 395:14-8. 2008
    ..Moreover, we focus on the most recent advances in the treatment of this disorder, which is primarily aimed to control bleeding episodes and to eradicate the autoantibody production...
  72. ncbi Acquired factor VIII inhibitors
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione, Azienda Ospedaliera Universitaria di Parma, Parma, Italy
    Blood 112:250-5. 2008
    ..If confirmed by large controlled studies, these innovative therapies might become a valid option for long-term eradication of factor VIII inhibitors...
  73. ncbi The use of recombinant activated factor VII in platelet-associated bleeding
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione Centro Emofilia, Azienda Ospedaliera di Verona, Verona, Italy
    Hematology 13:41-5. 2008
    ..The aim of this review is to summarize the current clinical experience on the use of rFVIIa in the management of bleeding associated with congenital or acquired platelet disorders...
  74. ncbi Drug-induced anti-factor VIII antibodies: a systematic review
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione Centro Emofilia, Azienda Ospedaliera di Verona, Verona, Italy
    Med Sci Monit 13:RA55-61. 2007
    ..3%). However, further studies are needed to better elucidate the epidemiology, natural history, clinical relevance, and optimal treatment of drug-associated factor VIII autoantibodies...
  75. ncbi Are thrombotic complications in patients with von Willebrand's disease expression of a multifactorial disease?
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione Centro Emofilia, Azienda Ospedaliera di Verona
    Haematologica 90:ECR34. 2005
  76. ncbi Inherited thrombophilia
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione, Azienda Ospedaliera di Verona, Verona, Italy
    Crit Rev Clin Lab Sci 43:249-90. 2006
    ..Finally, we discuss the synergism between genetic and acquired prothrombotic risk factors in particular conditions such as childhood and pregnancy...
  77. ncbi Treatment of chronic hepatitis C in haemophilic patients with interferon and ribavirin: a meta-analysis
    Massimo Franchini
    Hemophilia Center, City Hospital, Verona, Italy
    J Antimicrob Chemother 61:1191-200. 2008
    ..In order to analyse the effect of the current combination anti-HCV treatment [i.e. ribavirin plus interferon (IFN)] in this subset of HCV-infected patients, we performed a systematic review with meta-analysis of the available literature...
  78. ncbi Hemostasis and aging
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione, Centro Emofilia, Ospedale Policlinico, Piazzale Ludovico Scuro, Azienda Ospedaliera di Verona, 37134 Verona, Italy
    Crit Rev Oncol Hematol 60:144-51. 2006
    ..The complex inter-relationships between inherited and acquired factors influencing the hemostatic system during aging are discussed in this review...
  79. ncbi Inhibitors in mild/moderate haemophilia A: an update
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione Centro Emofilia, Ospedale Policlinico, Piazzale Ludovico Scuro, 37134 Verona, Italy
    Thromb Haemost 96:113-8. 2006
    ..In conclusion, large prospective trials are warranted in order to elucidate the many still unclear pathogenic and therapeutic aspects of the development of inhibitors in patients with mild/moderate hemophilia A...
  80. ncbi The use of recombinant activated factor VII in congenital and acquired von Willebrand disease
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione Centro Emofilia, Azienda Ospedaliera di Verona, Verona, Italy
    Blood Coagul Fibrinolysis 17:615-9. 2006
    ..Further studies are needed, however, to assess its safety and to optimize the dosages and regimens of therapy in such patients...
  81. ncbi Acquired von Willebrand syndrome: an update
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione Centro Emofilia, Azienda Ospedaliera di Verona, Verona, Italy
    Am J Hematol 82:368-75. 2007
    ..Through an analysis of the more recent literature data, the pathophysiology and the clinical, laboratory, and therapeutic aspects of this syndrome are concisely reported in this review...
  82. ncbi [Post-partum hemorrhage: new therapeutic options]
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione, Centro Emofilia, Azienda Ospedaliera, Verona
    Recenti Prog Med 98:7-11. 2007
    ..However, further evidences are needed in order to better assess the optimal dose, the effectiveness and the safety of rFVI-Ia in such critical bleeding conditions...
  83. ncbi Inflammation and hemostasis: a bidirectional interaction
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione Centro Emofilia, Azienda Ospedaliera di Verona, Italy
    Clin Lab 53:63-7. 2007
    ..This review focuses on the current understanding of the complex interactions between inflammation and coagulation...
  84. ncbi Hemostatic changes in thyroid diseases: haemostasis and thrombosis
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione Centro Emofilia, Azienda Ospedaliera di Verona, Verona, Italy
    Hematology 11:203-8. 2006
    ....
  85. ncbi Recombinant factor VIII concentrates
    Massimo Franchini
    Servizio di Immunoematologia e Medicina Trasfusionale, Dipartimento di Patologia e Medicina di Laboratorio, Azienda Ospedaliero Universitaria di Parma, Parma, Italy
    Semin Thromb Hemost 36:493-7. 2010
    ..In this article we review the current knowledge on the commercially available rFVIII concentrates, analyzing their main characteristics. Moreover, results of the literature on their clinical hemostatic efficacy and safety are summarized...
  86. ncbi Thyroid-associated autoimmune coagulation disorders
    Massimo Franchini
    Servizio di Immunoematologia e Medicina Trasfusionale, Dipartimento di Patologia e Medicina di Laboratorio, Azienda Ospedaliero Universitaria di Parma, Parma, Italy
    J Thromb Thrombolysis 29:87-91. 2010
    ..Finally, we conclude that the prompt recognition of possible concomitant autoimmune coagulation disorders is important for the correct management of these patients...
  87. ncbi Extracorporeal immunoadsorption for the treatment of coagulation inhibitors
    Massimo Franchini
    Immunohematology and Transfusion Center, University Hospital of Parma, Parma, Italy
    Semin Thromb Hemost 35:76-80. 2009
    ..However, further randomized clinical trials are needed to better assess the cost-effectiveness of such procedures...
  88. ncbi Interpatient phenotypic inconsistency in severe congenital hemophilia: a systematic review of the role of inherited thrombophilia
    Massimo Franchini
    Department of Pathology and Laboratory Medicine, Immunohematology and Transfusion Center, University Hospital of Parma, Italy
    Semin Thromb Hemost 35:307-12. 2009
    ..Further trials on a large population of patients are needed to establish the role of genetic thrombophilia in the phenotypic expression of severe hemophilia...
  89. ncbi The bidirectional relationship of cancer and hemostasis and the potential role of anticoagulant therapy in moderating thrombosis and cancer spread
    Massimo Franchini
    Immunohematology and Transfusion Center, Department of Pathology and Laboratory Medicine, University Hospital of Parma, Parma, Italy
    Semin Thromb Hemost 35:644-53. 2009
    ..The main biological and clinical evidence on the relationship between cancer and hemostasis are briefly summarized in this review, as is the potential benefits of anticoagulant therapy in this setting...
  90. ncbi Update on chronic hepatitis C in hemophiliacs
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione, Centro Emofilia, Ospedale Policlinico, via Delle Menegone 1, 37134 Verona, Italy
    Haematologica 87:542-9. 2002
    ..STATE OF THE ART AND PERSPECTIVES: We focus on the most important advances in the treatment of hepatitis C in hemophiliacs...
  91. ncbi Rituximab in the treatment of adult acquired hemophilia A: a systematic review
    Massimo Franchini
    Servizio di Immunoematologia e Trasfusione, Centro Emofilia, Ospedale Policlinico, Piazzale Ludovico Scuro, Azienda Ospedaliera di Verona, 37134 Verona, Italy
    Crit Rev Oncol Hematol 63:47-52. 2007
    ..However, large, prospective, randomized trials are needed to confirm these positive preliminary results...
  92. ncbi Unrelated allogeneic bone marrow donation: short- and long-term follow-up of 103 consecutive volunteer donors
    A Gandini
    Servizio di Immunoematologia e Trasfusione, Azienda Ospedaliera di Verona, Verona, Italy
    Bone Marrow Transplant 28:369-74. 2001
    ..1 months). All donors signed a written informed consent for a further bone marrow collection, if needed. Our findings confirm the short- and long-term safety of allogeneic bone marrow collection in volunteer donors...
  93. ncbi Switch off the light on cycling, switch off the light on doping
    G Lippi
    Sezione di Chimica Clinica, Dipartimento di Scienze Morfologico-Biomediche, , Ospedale Policlinico GB Rossi, Piazzale Scuro, 10, 37134 Verona, Italy
    Br J Sports Med 42:162. 2008
  94. ncbi Non-steroidal anti-inflammatory drugs in athletes
    G Lippi
    Department of Morphological-Biomedical Science, Institute of Chemical and Clinical Microscopy, University of Verona, Verona, Italy
    Br J Sports Med 40:661-2; discussion 662-3. 2006
  95. ncbi Total and free PSA serum concentrations are not influenced by extensive physical exercise and bicycle riding
    G Lippi
    Istituto di Chimica e Microscopia Clinica, Dipartimento di Scienze Morfologico-Biomediche, , Verona, Italy
    Int J Sports Med 26:79-81. 2005
    ..We hypothesize that neither a heavy and regular physical exercise nor the extensive and prolonged mechanical involvement of the prostate region by the bicycle riding have significant influence on release of both PSA and fPSA...
  96. ncbi Cobalt chloride administration in athletes: a new perspective in blood doping?
    G Lippi
    Ist Chimica e Microscopia Clinica, Universita di Verona, Verona, Italy
    Br J Sports Med 39:872-3. 2005
    ..Although there is as yet no direct or anecdotal evidence of cobalt chloride administration to athletes, its use should be warned against as being not only unfair but potentially dangerous...
  97. ncbi Genetic risk for recurrent urinary tract infections in humans: a systematic review
    M Zaffanello
    Department of Mother Child and Biology Genetics, Section of Pediatrics, University of Verona, Piazzale L Scuro 10, 37134 Verona, Italy
    J Biomed Biotechnol 2010:321082. 2010
    ..In particular, the HSPA1B, CXCR1 & 2, TLR2, TLR4, TGF-beta1 genes seem to be associated with an alteration of the host response to UTIs at various levels...
  98. ncbi Efficacy of Helicobacter pylori eradication in raising platelet count in adult patients with idiopathic thrombocytopenic purpura
    Dino Veneri
    Dipartimento di Medicina Clinica e Sperimentale, Divisione di Ematologia, Universita di Verona, Italy
    Haematologica 87:1177-9. 2002
    ..In addition, a significant increase of platelet count following HP eradication has been reported in a proportion of ITP patients. We describe here our experience on the efficacy of anti-HP treatment in ITP patients...
  99. ncbi Interactions between genotype and phenotype in bleeding and thrombosis
    Massimo Franchini
    Haematologica 93:649-52. 2008
    ..1 Examples of interactions between genotype and phenotype in both hemorrhagic and thrombotic disorders are given in this article...
  100. ncbi Remission of severe antiphospholipid syndrome associated with non-Hodgkin's B-cell lymphoma after combined treatment with rituximab and chemotherapy
    Dino Veneri
    Dipartimento di Medicina Clinica e Sperimentale, Sezione di Ematologia, Universita di Verona, Italy
    Haematologica 90:ECR37. 2005
    ..We describe one case of B-cell non-Hodgkinís lymphoma (NHL) in which the combination of rituximab with standard chemotherapy led to the complete remission of a severe hypercoagulable state associated with APA...
  101. ncbi Acquired haemophilia A as a blood transfusion emergency
    Giuseppe Tagariello
    Servizio Immunoematologia e Trasfusione, Centro Regionale per le Malattie del Sangue e Centro emofilia, ASL 8, Ospedale di Castelfranco Veneto, Castelfranco Veneto, Italy
    Blood Transfus 6:8-11. 2008
    ..Most reports on this condition describe the need for blood transfusions during the acute, haemorrhagic phase, but the number of transfused red cell units is often unknown...